List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5137209/publications.pdf Version: 2024-02-01



YU-PING NING

#	Article	IF	CITATIONS
1	Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Journal of Psychiatric Research, 2018, 106, 61-68.	3.1	119
2	Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. Journal of Affective Disorders, 2020, 265, 63-70.	4.1	68
3	Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain, Behavior, and Immunity, 2018, 74, 205-212.	4.1	63
4	Major depressive disorder and suicide risk among adult outpatients at several general hospitals in a Chinese Han population. PLoS ONE, 2017, 12, e0186143.	2.5	59
5	Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. Journal of Psychopharmacology, 2018, 32, 1118-1126.	4.0	53
6	Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. Journal of Affective Disorders, 2019, 246, 241-247.	4.1	50
7	A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. Journal of Affective Disorders, 2019, 251, 205-212.	4.1	46
8	Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder. Translational Psychiatry, 2020, 10, 246.	4.8	42
9	Hypomethylation of LINE-1 elements in schizophrenia and bipolar disorder. Journal of Psychiatric Research, 2018, 107, 68-72.	3.1	41
10	Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder. Psychoneuroendocrinology, 2019, 101, 72-79.	2.7	40
11	Cognitive Impairment and Structural Abnormalities in Late Life Depression with Olfactory Identification Impairment: an Alzheimer's Disease-Like Pattern. International Journal of Neuropsychopharmacology, 2018, 21, 640-648.	2.1	37
12	Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. Journal of Psychopharmacology, 2019, 33, 494-501.	4.0	35
13	A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. Journal of Affective Disorders, 2020, 275, 38-43.	4.1	31
14	Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers. Drug and Alcohol Dependence, 2014, 142, 290-294.	3.2	30
15	A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms. Frontiers in Cell and Developmental Biology, 2021, 9, 664535.	3.7	30
16	Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder: a longitudinal analysis. Translational Psychiatry, 2020, 10, 264.	4.8	28
17	Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. Journal of Affective Disorders, 2019, 259, 1-6.	4.1	27
18	Adjunctive minocycline for major mental disorders: A systematic review. Journal of Psychopharmacology, 2019, 33, 1215-1226.	4.0	27

#	Article	IF	CITATIONS
19	Impairment in the goal-directed corticostriatal learning system as a biomarker for obsessive–compulsive disorder. Psychological Medicine, 2020, 50, 1490-1500.	4.5	26
20	Expert consensus on the prevention and treatment of substance use and addictive behaviour-related disorders during the COVID-19 pandemic. Annals of General Psychiatry, 2020, 33, e100252.	3.1	26
21	Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. Journal of Neuroinflammation, 2021, 18, 200.	7.2	26
22	Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Schizophrenia Research, 2018, 197, 288-293.	2.0	25
23	Interactive Effect of Depression and Cognitive Impairment on Olfactory Identification in Elderly People. Journal of Alzheimer's Disease, 2018, 66, 1645-1655.	2.6	19
24	Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder. Journal of Affective Disorders, 2020, 276, 608-615.	4.1	19
25	<p>Increased Plasma Kynurenic Acid Levels are Associated with Impaired Attention/Vigilance and Social Cognition in Patients with Schizophrenia</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 263-271.	2.2	18
26	Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 431-438.	3.2	17
27	Association between depression subtypes and response to repeatedâ€dose intravenous ketamine. Acta Psychiatrica Scandinavica, 2019, 140, 446-457.	4.5	16
28	Association between cognition and suicidal ideation in patients with major depressive disorder: A longitudinal study. Journal of Affective Disorders, 2020, 272, 146-151.	4.1	16
29	Gender differences in the prevalence and clinical correlates of sleep disturbance in general hospital outpatients. Psychiatry Research, 2018, 269, 134-139.	3.3	15
30	Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis. Journal of Affective Disorders, 2020, 264, 263-271.	4.1	15
31	Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis. Pharmacological Reports, 2021, 73, 594-603.	3.3	15
32	Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression. Journal of Affective Disorders, 2022, 300, 109-113.	4.1	15
33	Interactive effects of elevated homocysteine and late-life depression on cognitive impairment. Journal of Affective Disorders, 2020, 277, 212-217.	4.1	14
34	Prevalence, clinical correlates and IQ of suicidal ideation in drug naÃ ⁻ ve Chinese Han patients with major depressive disorder. Journal of Affective Disorders, 2019, 248, 59-64.	4.1	13
35	Difference of olfactory deficit in patients with acute episode of schizophrenia and major depressive episode. Schizophrenia Research, 2019, 212, 99-106.	2.0	12
36	The additive effect of late-life depression and olfactory dysfunction on the risk of dementia was mediated by hypersynchronization of the hippocampus/fusiform gyrus. Translational Psychiatry, 2021, 11, 172.	4.8	12

#	Article	IF	CITATIONS
37	The interaction between estradiol change and the serotonin transporter gene (5-HTTLPR) polymorphism is associated with postpartum depressive symptoms. Psychiatric Genetics, 2019, 29, 97-102.	1.1	10
38	BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 901-908.	2.2	9
39	Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. Journal of Psychopharmacology, 2021, 35, 159-167.	4.0	9
40	The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. Journal of Psychiatric Research, 2021, 144, 312-319.	3.1	9
41	Consistent brain structural abnormalities and multisite individualised classification of schizophrenia using deep neural networks. British Journal of Psychiatry, 2022, 221, 732-739.	2.8	9
42	Functional connectivity between the habenula and default mode network and its association with the antidepressant effect of ketamine. Depression and Anxiety, 2022, 39, 352-362.	4.1	9
43	The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder. Journal of Affective Disorders, 2021, 287, 327-333.	4.1	8
44	Retrospective assessment of factors associated with readmission in a large psychiatric hospital in Guangzhou, China. Shanghai Archives of Psychiatry, 2014, 26, 138-48.	0.7	8
45	Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532097379.	2.7	7
46	Prevalence and risk factors for mental health symptoms in community epidemic prevention workers during the postpandemic era of COVID-19 in China. Psychiatry Research, 2021, 304, 114132.	3.3	7
47	Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study. Journal of Affective Disorders, 2020, 271, 1-8.	4.1	6
48	Diabetes in late-life schizophrenia: Prevalence, factors, and association with clinical symptoms. Journal of Psychiatric Research, 2021, 132, 44-49.	3.1	6
49	Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression. Frontiers in Psychiatry, 2021, 12, 780975.	2.6	6
50	Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. Journal of Affective Disorders, 2022, 300, 172-178.	4.1	6
51	The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. Journal of Affective Disorders, 2022, 304, 78-84.	4.1	6
52	Odor-related brain hyper-reactivity in euthymic bipolar disorder: An fMRI and ERP study. Psychiatry Research, 2019, 278, 218-227.	3.3	5
53	A Preliminary Study of Adjunctive Nonconvulsive Electrotherapy for Treatment-Refractory Depression. Psychiatric Quarterly, 2021, 92, 311-320.	2.1	5
54	Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110143.	2.7	5

#	Article	IF	CITATIONS
55	Development of a checklist of short-term and long-term psychological symptoms associated with ketamine use. Shanghai Archives of Psychiatry, 2015, 27, 186-94.	0.7	5
56	Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study. PeerJ, 2020, 8, e10208.	2.0	5
57	Neuropsychiatric Symptoms Mediated the Relationship Between Odor Identification and Cognition in Alzheimer's Disease Spectrum: A Structural Equation Model Analysis. Frontiers in Aging Neuroscience, 2021, 13, 732840.	3.4	5
58	Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis. Journal of Affective Disorders, 2022, 304, 59-65.	4.1	5
59	Mediating effect of neurocognition between severity of symptoms and social-occupational function in anxious depression. Journal of Affective Disorders, 2019, 246, 667-673.	4.1	4
60	Determining the effects of LLD and MCI on brain decline according to machine learning and a structural covariance network analysis. Journal of Psychiatric Research, 2020, 126, 43-54.	3.1	4
61	<p>Serum BDNF Levels are Not Associated with the Antidepressant Effects of Nonconvulsive Electrotherapy</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1555-1560.	2.2	4
62	Reduction of phonetic mismatch negativity may depict illness course and predict functional outcomes in schizophrenia. Journal of Psychiatric Research, 2021, 137, 290-297.	3.1	4
63	Differences in Odor Identification in Early-Onset and Late-Onset Depression. Brain Sciences, 2022, 12, 276.	2.3	4
64	Plasma VEGF Concentrations and Ketamine's Effects on Suicidal Ideation in Depression With Suicidal Ideation. Frontiers in Psychiatry, 2022, 13, 855995.	2.6	4
65	Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation. Frontiers in Psychiatry, 2022, 13, 779326.	2.6	4
66	Resting-state functional connectivity of the amygdala in major depressive disorder with suicidal ideation. Journal of Psychiatric Research, 2022, 153, 189-196.	3.1	4
67	Prevalence and risk factors for depression in outpatient departments of three general hospitals in China: a cross-sectional study. International Journal of Psychiatry in Clinical Practice, 2020, 24, 88-95.	2.4	3
68	Physical Comorbidities are Independently Associated with Higher Rates of Psychiatric Readmission in a Chinese Han Population. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2073-2082.	2.2	3
69	Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies - Authors' reply. Journal of Affective Disorders, 2020, 274, 955.	4.1	3
70	Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2827-2836.	2.2	3
71	The challenge and response of mental health institutions in COVID-19 pandemic: from chaos to new normal. Translational Psychiatry, 2020, 10, 386.	4.8	3
72	Interactive Effects of Agitation and Cognitive Impairment on Odor Identification in Patients With Late-Life Depression. Frontiers in Psychiatry, 2022, 13, 839012.	2.6	3

#	Article	IF	CITATIONS
73	Disrupted olfactory functional connectivity in patients with late-life depression. Journal of Affective Disorders, 2022, 306, 174-181.	4.1	3
74	Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients. Frontiers in Psychiatry, 2022, 13, 793677.	2.6	2
75	Aberrant Dynamic Functional Connectivity of Posterior Cingulate Cortex Subregions in Major Depressive Disorder With Suicidal Ideation. Frontiers in Neuroscience, 0, 16, .	2.8	2